Si Wei Xu, Jun Feng Liu, Yu Rong, Xin Bo Liu, Zhi Hua Shi, Bing Ji Cao, Shao Wei Zhang
{"title":"胸中、下段鳞状细胞癌食管切除术中隆下淋巴结清扫对预后的影响。","authors":"Si Wei Xu, Jun Feng Liu, Yu Rong, Xin Bo Liu, Zhi Hua Shi, Bing Ji Cao, Shao Wei Zhang","doi":"10.1093/icvts/ivaf219","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective study assesses the prognostic value of subcarinal lymph node dissection (SCLND) in esophageal squamous cell carcinoma (ESCC) of the middle and lower thoracic regions.</p><p><strong>Methods: </strong>The study, conducted at the Fourth Hospital of Hebei Medical University, included 1587 patients with ESCC who underwent radical resection from 2008 to 2014, comprising 204 patients in the non-SCLND group and 1383 patients in the SCLND group. After applying inverse probability of treatment weighting (IPTW) to adjust for confounders, Kaplan-Meier curves, log-rank tests, and Cox regression were used for survival analysis, performed using R.</p><p><strong>Results: </strong>SCLN metastasis was found in 9.8% of patients. Factors influencing metastasis included pathologic T stage (P < 0.001) and N stage (P < 0.001). SCLN metastasis significantly affected overall survival, with 5-year rates of 49.0% for non-metastatic versus 7.0% for metastatic patients. SCLND improved long-term survival for T3-T4a stage patients but not for T1-T2.</p><p><strong>Conclusions: </strong>Despite a low SCLN metastasis rate, its presence significantly worsens prognosis. SCLND does not significantly improve long-term survival in patients with pathologic T1-T2 tumors, but it may confer a survival benefit in T3-T4a stage disease, supporting individualized surgical decisions regarding lymph node dissection.</p>","PeriodicalId":73406,"journal":{"name":"Interdisciplinary cardiovascular and thoracic surgery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12526115/pdf/","citationCount":"0","resultStr":"{\"title\":\"The prognostic significance of subcarinal lymph node dissection in esophagectomy for middle and lower thoracic squamous cell carcinoma.\",\"authors\":\"Si Wei Xu, Jun Feng Liu, Yu Rong, Xin Bo Liu, Zhi Hua Shi, Bing Ji Cao, Shao Wei Zhang\",\"doi\":\"10.1093/icvts/ivaf219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This retrospective study assesses the prognostic value of subcarinal lymph node dissection (SCLND) in esophageal squamous cell carcinoma (ESCC) of the middle and lower thoracic regions.</p><p><strong>Methods: </strong>The study, conducted at the Fourth Hospital of Hebei Medical University, included 1587 patients with ESCC who underwent radical resection from 2008 to 2014, comprising 204 patients in the non-SCLND group and 1383 patients in the SCLND group. After applying inverse probability of treatment weighting (IPTW) to adjust for confounders, Kaplan-Meier curves, log-rank tests, and Cox regression were used for survival analysis, performed using R.</p><p><strong>Results: </strong>SCLN metastasis was found in 9.8% of patients. Factors influencing metastasis included pathologic T stage (P < 0.001) and N stage (P < 0.001). SCLN metastasis significantly affected overall survival, with 5-year rates of 49.0% for non-metastatic versus 7.0% for metastatic patients. SCLND improved long-term survival for T3-T4a stage patients but not for T1-T2.</p><p><strong>Conclusions: </strong>Despite a low SCLN metastasis rate, its presence significantly worsens prognosis. SCLND does not significantly improve long-term survival in patients with pathologic T1-T2 tumors, but it may confer a survival benefit in T3-T4a stage disease, supporting individualized surgical decisions regarding lymph node dissection.</p>\",\"PeriodicalId\":73406,\"journal\":{\"name\":\"Interdisciplinary cardiovascular and thoracic surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12526115/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interdisciplinary cardiovascular and thoracic surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/icvts/ivaf219\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interdisciplinary cardiovascular and thoracic surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/icvts/ivaf219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
The prognostic significance of subcarinal lymph node dissection in esophagectomy for middle and lower thoracic squamous cell carcinoma.
Objectives: This retrospective study assesses the prognostic value of subcarinal lymph node dissection (SCLND) in esophageal squamous cell carcinoma (ESCC) of the middle and lower thoracic regions.
Methods: The study, conducted at the Fourth Hospital of Hebei Medical University, included 1587 patients with ESCC who underwent radical resection from 2008 to 2014, comprising 204 patients in the non-SCLND group and 1383 patients in the SCLND group. After applying inverse probability of treatment weighting (IPTW) to adjust for confounders, Kaplan-Meier curves, log-rank tests, and Cox regression were used for survival analysis, performed using R.
Results: SCLN metastasis was found in 9.8% of patients. Factors influencing metastasis included pathologic T stage (P < 0.001) and N stage (P < 0.001). SCLN metastasis significantly affected overall survival, with 5-year rates of 49.0% for non-metastatic versus 7.0% for metastatic patients. SCLND improved long-term survival for T3-T4a stage patients but not for T1-T2.
Conclusions: Despite a low SCLN metastasis rate, its presence significantly worsens prognosis. SCLND does not significantly improve long-term survival in patients with pathologic T1-T2 tumors, but it may confer a survival benefit in T3-T4a stage disease, supporting individualized surgical decisions regarding lymph node dissection.